<DOC>
	<DOCNO>NCT02889861</DOCNO>
	<brief_summary>IMCgp100-401 rollover study design provide continued access IMCgp100 eligible patient advance melanoma previously participate IMCgp100 study ( parent study ) .</brief_summary>
	<brief_title>IMCgp100-401 Rollover Study</brief_title>
	<detailed_description>IMCgp100-401 rollover study design provide continued access IMCgp100 eligible patient advance melanoma previously participate IMCgp100 study ( parent study ) . Parent study eligible patient continue receive IMCgp100 rollover study must complete satisfied primary endpoint terminate Sponsor reason safety . Eligible patient tolerate IMCgp100 minimum 4 week dose without significant toxicity would preclude dose opinion principal investigator Sponsor .</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<criteria>1 . Patient currently participate Immunocoresponsored study IMCgp100 actively receive IMCgp100 . Patient must fulfil required assessment parent study ( unless study terminate ) 2 . Patient currently receive clinical benefit treatment IMCgp100 , determine principal investigator parent study 3 . Patient demonstrate compliance parent study requirement , assess principal investigator patient able comply necessary visit assessment part rollover study 4 . Written informed consent must obtain prior enrol rollover study receive study treatment . If consent express writing , consent must formally document witnessed , ideally via independent trust witness 1 . Patient permanently discontinue IMCgp100 study IMCgp100 treatment parent study due unequivocal progressive disease , unacceptable toxicity , noncompliance study procedure , withdrawal consent , reason 2 . Pregnant nursing ( lactate ) woman , pregnancy define state female conception termination gestation , confirm positive human chorionic gonadotropin laboratory test 3 . Women childbearing potential sexually active nonsterilized male partner , define woman physiologically capable become pregnant , unless use 2 method highly effective contraception Screening , must agree continue use precaution 6 month final dose investigational product ; cessation birth control point discuss responsible physician . Highly effective method include barrier method , intrauterine device hormonal method . Periodic abstinence , rhythm method , withdrawal method acceptable method birth control . Women childbearing potential must negative serum pregnancy test Screening . Otherwise , female patient must postmenopausal ( menstrual period least 12 month prior Screening ) , surgically sterile 4 . Male patient surgically sterile unless use double barrier contraception method enrollment treatment 6 month follow administration last dose study drug</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Uveal melanoma</keyword>
	<keyword>Cutaneous melanoma</keyword>
</DOC>